Hepion shareholders reject reverse stock split amendment at 2025 annual meeting

Hepion Pharmaceuticals, Inc.

Reverse stock split proposal (1:5 to 1:20) failed with 2.25M for, 3.70M against; not approved.
All four director nominees (Brancaccio, Block, Lbiati, Purcell) elected despite majority of votes withheld.
Ratification of Grassi & Co. as auditors passed with 4.76M for vs 1.17M against.
Advisory say-on-pay failed with 162K for, 337K against.
Only 10.9M shares outstanding; broker non-votes totaled 5.46M on most proposals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.